Ylinen A, Pitkänen M, Sirviö J, Hartikainen T, Sivenius J, Koivisto E, Riekkinen P J
Department of Neurology, University of Kuopio, Finland.
Eur J Pharmacol. 1995 Feb 14;274(1-3):159-65. doi: 10.1016/0014-2999(94)00729-q.
In the present study we investigated the effects of two competitive NMDA receptor antagonists, CGP 37849 (DL-(E)-2-amino-4-methyl-phosphono-3-pentonoic acid) and CGP 39551 (carboxyethyl ester of CGP 37849) as well as MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenz(a,d)cycloheptene-5,10-imine hydrogen maleate), a non-competitive antagonist, administered systemically before training, on the acquisition of a water maze task used to assess spatial learning and memory in rats. The competitive NMDA receptor antagonists dose dependently impaired water maze acquisition (increased escape distance), but did not significantly affect swimming speed in rats. MK-801 induced clear behavioral effects and impaired the acquisition of the water maze task. However, as training advanced drug-treated rats did show a decrease in distance swam per trial before encountering the platform in the water pool. This suggests that drug treatments did not abolish learning. When the anticonvulsive properties of the drugs were determined, MK-801 did not show any protection in the maximal electroshock (MES) test at doses already impairing the acquisition of the water maze task while the two competitive NMDA receptor antagonists protected the rats against seizures at doses not impairing acquisition. This result suggests a wider therapeutic range for CGP 39551 and especially for CGP 37849 than for MK-801 in the treatment of epilepsy.
在本研究中,我们调查了两种竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂CGP 37849(DL-(E)-2-氨基-4-甲基-膦酰基-3-戊酸)和CGP 39551(CGP 37849的羧乙基酯)以及非竞争性拮抗剂MK-801((+)-5-甲基-10,11-二氢-5H-二苯并(a,d)环庚烯-5,10-亚胺氢马来酸盐)在训练前全身给药时,对用于评估大鼠空间学习和记忆的水迷宫任务习得的影响。竞争性NMDA受体拮抗剂剂量依赖性地损害水迷宫任务的习得(增加逃避距离),但对大鼠的游泳速度没有显著影响。MK-801诱导了明显的行为效应并损害了水迷宫任务的习得。然而,随着训练的进行,药物处理的大鼠在水池中遇到平台之前每次试验的游泳距离确实有所减少。这表明药物处理并没有消除学习。当测定药物的抗惊厥特性时,在已经损害水迷宫任务习得的剂量下,MK-801在最大电休克(MES)试验中没有显示出任何保护作用,而两种竞争性NMDA受体拮抗剂在不损害习得的剂量下保护大鼠免受癫痫发作。该结果表明,在癫痫治疗中,CGP 39551尤其是CGP 37849的治疗范围比MK-801更广。